Who is Retatrutide 40 mg for Retatrutide is an investigational drug (Phase 3), not yet approved by the FDA/EMA Triple GLP-1 / GIP / glucagon agonist a unique mechanism of action For patients for whom single (Ozempic) or dual (Mounjaro) agonists did not deliver enough effect Strictly under medical supervision Retatrutide 40 mg compared to other doses Retatrutide 12 mg showed ~24% weight loss over 48 weeks (Phase 2, NEJM 2023) Compared to Mounjaro 15 mg (~2226%) a similar effect, but with a triple mechanism Key difference: retatrutide activates the glucagon receptor, increasing energy expenditure No final Phase 3 results yet efficacy and safety are still being confirmed FAQ about Retatrutide 40 mg (ALLUVI) 1 ALLUVI Retatrutide injection pen (40 mg total, dial mechanism up to 10 mg per dose), 12 single-use ALLUVI needles and dosing instructions (Dosage Guide) with step-by-step schedule from 2.5 mg to 10 mg
FTC Affiliate Disclosure: This article contains affiliate links
$35 Learn More Add To Cart Powerful Duo Bundle and Save Metabolic Daily Bundle Couple our flagship probiotic with its favorite food (polyphenols) and increase the benefits
A single 30mg vial at 12mg weekly lasts longer than a 20mg vial, reducing your reconstitution frequency and keeping your protocol cleaner
We are committed to providing our patients with the most advanced options for managing weight, diabetes, and overall metabolic health
The verifiable ones check out
